Ingelheim – The Company Headquarters
Located within proximity to Frankfurt, Ingelheim has been hosting the headquarters of Boehringer Ingelheim ever since the foundation of the company in 1885. At that time, Albert Boehringer purchased a small tartaric acid factory. Over the course of the 20th century, the company gradually expanded from Ingelheim to become one of the leading, research-driven biopharmaceutical companies in the world. Today, more than 9,000 employees work at the Ingelheim site in Production, Research, Development, and Administration.
On these vast company grounds with more than 750,000 square meters, Boehringer Ingelheim produces various pharmaceuticals, including SPIRIVA® inhalation capsules, the oral anticoagulant PRADAXA® as well as the diabetes medications SYNJARDY® and JENTADUETO®. Within the company’s global production network, Ingelheim is also responsible for the production of all new active ingredients and medications during the market launch.
Boehringer Ingelheim continues to advance its home site by constant investments. For instance, the Solids Launch plant (SOL) was inaugurated in October 2021. At this plant, all new solid products, i.e. pharmaceuticals available as tablets, are centrally manufactured for the market launch phase.